TOPIC
VACCINES News & Analysis
Stocks
Fresh pandemic fears may stoke demand for these vaccine makers.
Vikram Barhat | 08 December 2022
Stocks
We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.
Damien Conover | 24 September 2021
Video
Are there still opportunities in the biotech sector now the covid-19 vaccine roll out is underway? We ask International Biotechnology Trust manager...
Holly Black | 22 June 2021
Stocks
A resurgence in domestic travel is tipped to tide travel operators over until international borders open.
Lewis Jackson | 26 May 2021
Stocks
We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.
Karen Andersen, CFA | 07 May 2021
Stocks
Subsectors such as biotechnology, pharmaceuticals and diagnostics feature some globally listed names that are trading at discounts.
Lex Hall | 16 March 2021
Stocks
Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.
Morningstar.com.au | 19 January 2021
Stocks
Covid will create a $52bn vaccine and treatment market and usher in immunity by 2023, writes Morningstar's Karen Andersen.
Karen Andersen, CFA | 11 January 2021
Stocks
The plasma giant remains overvalued, according to Morningstar.
Emma Rapaport | 14 December 2020
Stocks
Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.
Damien Conover, CFA | 24 November 2020
of 7
Viewing 1 to 10 of 64